Skip to content

Study · Animal study (in vivo) · rat · 2019

9 results

Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation.

Sever AZ, Sever M, Vidovic T, Lojo N, Kolenc D, Vuletic LB, Drmic D, Kokot A, Zoricic I, Coric M, Vlainic J, Poljak L, Seiwerth S, Sikiric P

European journal of pharmacology25 Jan 2019Cited by 48 (Europe PMC)

PMID30690000 (opens in a new tab)DOI10.1016/j.ejphar.2019.01.030 (opens in a new tab)PepBankPUB-30690000
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 therapy markedly abated jaundice, ascites, nodular and steatotic liver with dilatation of the main bile duct, and increased liver and/or cyst weight.

    In plain wordsIn rats with a tied bile duct, BPC‑157 reduced jaundice, fluid in the belly and signs of liver damage.

    Peptide
    BPC-157
    Outcome
    DecreaseJaundice, ascites and gross liver changes (nodular, steatotic liver, bile duct dilatation, liver and/or cyst weight)
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Comparator
    Controls
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    BPC 157 therapy markedly abated jaundice, snout, ears, paws, and yellow abdominal tegmentum in controls since 4th week, ascites, nodular, steatotic liver with large dilatation of main bile duct, increased liver and/or cyst weight, decreased body weight.
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 therapy abated the decreased body weight seen in controls.

    In plain wordsIn rats with a tied bile duct, BPC‑157 reduced the loss of body weight seen in control rats.

    Peptide
    BPC-157
    Outcome
    IncreaseBody weight decrease in bile duct ligation
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Comparator
    Controls
    Outcome group
    Body weight · Whole body
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    BPC 157 therapy markedly abated jaundice, snout, ears, paws, and yellow abdominal tegmentum in controls since 4th week, ascites, nodular, steatotic liver with large dilatation of main bile duct, increased liver and/or cyst weight, decreased body weight.
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 counteracted piecemeal necrosis, focal lytic necrosis, apoptosis and focal inflammation in the liver.

    In plain wordsIn rats with a tied bile duct, BPC‑157 reduced liver cell death and local inflammation.

    Peptide
    BPC-157
    Outcome
    DecreasePiecemeal necrosis, focal lytic necrosis, apoptosis and focal inflammation of liver
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    BPC 157 counteracts the piecemeal necrosis, focal lytic necrosis, apoptosis and focal inflammation, disturbed cell proliferation (Ki-67-staining), cytoskeletal structure in the hepatic stellate cell (α-SMA staining), collagen presentation (Mallory staining).
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 counteracted disturbed cell proliferation (Ki-67 staining), changes in hepatic stellate cell cytoskeletal structure (α-SMA staining) and collagen presentation (Mallory staining).

    In plain wordsIn rats with a tied bile duct, BPC‑157 counteracted disturbed cell proliferation, stellate cell structure and collagen presentation in the liver.

    Peptide
    BPC-157
    Outcome
    Direction not reportedDisturbed cell proliferation (Ki-67), hepatic stellate cell cytoskeleton (α-SMA) and collagen presentation (Mallory)
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    BPC 157 counteracts the piecemeal necrosis, focal lytic necrosis, apoptosis and focal inflammation, disturbed cell proliferation (Ki-67-staining), cytoskeletal structure in the hepatic stellate cell (α-SMA staining), collagen presentation (Mallory staining).
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 counteracted increased serum AST, ALT, GGT, ALP and total, direct and indirect bilirubin.

    In plain wordsIn rats with a tied bile duct, BPC‑157 reduced high blood levels of liver enzymes and bilirubin.

    Peptide
    BPC-157
    Outcome
    DecreaseSerum AST, ALT, GGT, ALP and bilirubin increases
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    Likewise, counteraction includes increased AST, ALT, GGT, ALP, total bilirubin, direct and indirect
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 counteracted the decreased serum albumin level.

    In plain wordsIn rats with a tied bile duct, BPC‑157 reduced the drop in blood albumin.

    Peptide
    BPC-157
    Outcome
    IncreaseSerum albumin decrease
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    Likewise, counteraction includes increased AST, ALT, GGT, ALP, total bilirubin, direct and indirect and decreased albumin serum levels.
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 therapy ended with normalized MDA and NO tissue values in the liver.

    In plain wordsIn rats with a tied bile duct, BPC‑157 brought two liver stress markers, MDA and NO, back to normal values.

    Peptide
    BPC-157
    Outcome
    MixedMDA and NO tissue values in liver
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Oxidative stress · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    As the end-result appear normalized MDA- and NO-tissue values, next to Western blot of NOS2 and NOS3 in the liver tissue, and decreased IL-6, TNF-α, IL-1β levels in liver tissue.
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 therapy was followed by decreased IL-6, TNF-α and IL-1β levels in liver tissue.

    In plain wordsIn rats with a tied bile duct, BPC‑157 was followed by lower levels of three inflammation proteins in liver tissue.

    Peptide
    BPC-157
    Outcome
    DecreaseLiver tissue IL-6, TNF-α and IL-1β levels
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    As the end-result appear normalized MDA- and NO-tissue values, next to Western blot of NOS2 and NOS3 in the liver tissue, and decreased IL-6, TNF-α, IL-1β levels in liver tissue.
    2 context sentences
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with bile duct ligation, BPC‑157 therapy either prevented portal hypertension from developing or rapidly abated it, depending on the regimen.

    In plain wordsIn rats with a tied bile duct, BPC‑157 either stopped high portal vein pressure from developing or quickly lowered it.

    Peptide
    BPC-157
    Outcome
    DecreasePortal hypertension
    Study

    Ratsn: not reported in source

    Bile duct ligation (BDL), sacrifice at 2, 4, 6, 8 week
    Outcome group
    Blood pressure · Liver
    Studied dose
    10 μg/kg, 10 ng/kg · Drinking water (continuous), intraperitoneal, and local bath · In drinking water continuously since awakening from surgery or since week 4; intraperitoneal first at 30 min post-ligation, last at 24 h before sacrifice; sacrifice at 2, 4, 6, 8 weekAs given in this study (Rats).

    Source sentences

    Summary
    Finally, although portal hypertension is sustained in BDL-rats, with BPC 157 therapy, portal hypertension in BDL-rats is either not even developed or rapidly abated, depending on the given BPC 157's regimen.
    3 context sentences
    Summary · context
    Local bath BPC 157 (10 µg/kg) with assessed immediate normalization of portal hypertension was given immediately after establishing portal hypertension values at 4, 6, 8 week.
    Summary · context
    BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4.
    Summary · context
    rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.